Instrument Inactif

Communiqués Guided Therapeutics Inc OTC Bulletin Board

Actions

US40171F3038

Equipement et technologie médicale avancés

Communiqués

16/06	Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA	BU
31/03	Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering	BU
17/12	Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva	BU
11/12	Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor	BU
19/11	Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation	BU
19/08/25	Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings	BU
13/08/25	Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial	BU
02/07/25	Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.	BU
10/06/25	Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor	BU
27/05/25	Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China	BU
23/12/24	Guided Therapeutics : Material Agreement Form 8 K	PU
10/12/24	Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables	BU
22/10/24	Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China	BU
10/07/24	Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results	BU
20/02/24	Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results	BU
20/11/23	Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval	BU
01/05/23	Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval	BU
30/03/23	GUIDED THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS (form 10-K)	AQ
15/03/23	Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation	BU
09/03/23	GUIDED THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)	AQ
21/12/22	Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval	BU
14/11/22	GUIDED THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
09/11/22	Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan	BU
15/09/22	GUIDED THERAPEUTICS INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
07/09/22	Guided Therapeutics Closes $3.3 Million Bridge Financing	BU